Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 9/20 | 0.51 |
| ▸ | ALB | P02768 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1417544 | 1.00 | TK1 (0.51) | TK1ALBPKM | |
| SCHEMBL12942599 | 0.89 | TK1 (0.55) | TK1ALBPKM | |
| SCHEMBL913905 | 0.89 | TK1 (0.55) | TK1ALBPKM | |
| SCHEMBL31653051 | 0.89 | TK1 (0.55) | TK1ALBPKM | |
| SCHEMBL31652938 | 0.89 | TK1 (0.55) | TK1ALBPKM | |
| SCHEMBL31652832 | 0.89 | TK1 (0.55) | TK1ALBPKM | |
| SCHEMBL913904 | 0.89 | TK1 (0.55) | TK1ALBPKM | |
| SCHEMBL31652953 | 0.88 | TK1 (0.50) | TK1ALBPKM | |
| SCHEMBL31652964 | 0.87 | TK1 (0.38) | TK1 | |
| SCHEMBL31653010 | 0.87 | PYGM (0.43) | TK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2509949-B1 | PYRIDINONE HYDROXYCYCLOPENTYL CARBOXAMIDES: HIV INTEGRASE INHIBITORS WITH THERAPEUTIC APPLICATIONS | UNIV GEORGIA (US) | 2014-04-23 | — | — | EP | claimed |
| US-8703801-B2 | Pyridinone hydroxycyclopentyl carboxamides: HIV integrase inhibitors with therapeutic applications | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2014-04-22 | — | — | US | claimed |
| US-20120282218-A1 | PYRIDINONE HYDROXYCYCLOPENTYL CARBOXAMIDES: HIV INTEGRASE INHIBITORS WITH THERAPEUTIC APPLICATIONS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION INC. (US) | 2012-11-08 | — | — | US | claimed |
| EP-2509949-A2 | PYRIDINONE HYDROXYCYCLOPENTYL CARBOXAMIDES: HIV INTEGRASE INHIBITORS WITH THERAPEUTIC APPLICATIONS | University Of Georgia Research Foundation, Inc. (US) | 2012-10-17 | — | — | EP | claimed |
| WO-2011071849-A2 | PYRIDINONE HYDROXYCYCLOPENTYL CARBOXAMIDES: HIV INTEGRASE INHIBITORS WITH THERAPEUTIC APPLICATIONS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2011-06-16 | — | — | WO | claimed |
| US-20100092427-A1 | Pyridinone Diketo Acids: Inhibitors of HIV Replication in Combination Therapy | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION (US) | 2010-04-15 | — | — | US | claimed |
| EP-2046328-A2 | PYRIDINONE DIKETO ACIDS: INHIBITORS OF HIV REPLICATION IN COMBINATION THERAPY | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2009-04-15 | — | — | EP | claimed |
| WO-2008010953-A2 | PYRIDINONE DIKETO ACIDS: INHIBITORS OF HIV REPLICATION IN COMBINATION THERAPY | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2008-01-24 | — | — | WO | claimed |
| US-20070264241-A1 | Compounds for Enhanced Cancer Therapy | ZGENE A/S (DK) | 2007-11-15 | — | — | US | claimed |
| WO-2007106450-A2 | DIKETO ACIDS WITH NUCLEOBASE SCAFFOLDS: ANTI-HIV REPLICATION INHIBITORS TARGETED AT HIV INTEGRASE IN COMBINATION THERAPY | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2007-09-20 | — | — | WO | claimed |
| US-20050026902-A1 | Methods and compositions for the treatment or prevention of human immunodeficiency virus and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents | PHARMACIA CORPORATION | 2005-02-03 | — | — | US | claimed |
| US-5192749-A | Viricide, AIDS | SYNTEX (U.S.A.) INC. (US) | 1993-03-09 | — | — | US | claimed |
| US-20250215039-A1 | NUCLEOSIDES FOR TREATING CANCER | PRIMEFOUR THERAPEUTICS INC (US) | 2025-07-03 | — | — | US | disclosed |
| US-20230293526-A1 | METHOD FOR TREATING CANCER WITH A REVERSE TRANSCRIPTASE INHIBITOR | PRIMEFOUR THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| WO-2022256625-A1 | LINE-1 INHIBITORS AS COGNITIVE ENHANCERS | TRANSPOSON THERAPEUTICS, INC. (US) | 2022-12-08 | — | — | WO | disclosed |
| EP-2298783-B1 | Anti-viral nucleoside analogs and methods for treating viral infections, especially hiv infections | UNIV YALE (US) | 2017-12-06 | — | — | EP | disclosed |
| WO-2005005626-A1 | YELLOW FEVER MOSQUITO DEOXYRIBONUCLEOSIDE KINASES AND ITS USE | ZGENE A/S (DK) | 2005-01-20 | — | — | WO | disclosed |
| US-20040167096-A1 | Anti-viral nucleoside analogs and methods for treating viral infections, especially HIV infections | YALE UNIVERSITY | 2004-08-26 | — | — | US | disclosed |
| WO-2004003185-A2 | PLANT DEOXYRIBONUCLEOSIDE KINASE ENZYMES AND THEIR USE | KNECHT WOLFGANG (SE) | 2004-01-08 | — | — | WO | disclosed |
| US-5192749-A | Viricide, AIDS | SYNTEX (U.S.A.) INC. (US) | 1993-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230293526-A1 | METHOD FOR TREATING CANCER WITH A REVERSE TRANSCRIPTASE INHIBITOR | TYMP, TYMS, DCTD | TK1 16/4885ALB 2901/4885PKM 3224/4885 |
| US-20100092427-A1 | Pyridinone Diketo Acids: Inhibitors of HIV Replication in Combination Therapy | TKT, DHFR, DTYMK | TK1 7/4885ALB 4476/4885PKM 24/4885 |
| US-20120282218-A1 | PYRIDINONE HYDROXYCYCLOPENTYL CARBOXAMIDES: HIV INTEGRASE INHIBITORS WITH THERAPEUTIC APPLICATIONS | PAICS, DUT, AADAC | TK1 54/4885ALB 4691/4885PKM 792/4885 |
| US-20070264241-A1 | Compounds for Enhanced Cancer Therapy | TYMP, BAD, NUDT1 | TK1 16/4885ALB 4112/4885PKM 1149/4885 |
| US-20250215039-A1 | NUCLEOSIDES FOR TREATING CANCER | UNG, OGG1, NTPCR | TK1 117/4885ALB 4851/4885PKM 3116/4885 |
| US-20040167096-A1 | Anti-viral nucleoside analogs and methods for treating viral infections, especially HIV infections | CCR1, CCR4, CCR3 | TK1 92/4885ALB 3757/4885PKM 3531/4885 |
| US-20050026902-A1 | Methods and compositions for the treatment or prevention of human immunodeficiency virus and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents | PTGS2, PTGS1, PTGES2 | TK1 385/4885ALB 4205/4885PKM 2922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.